Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
Sorafenib has been shown to inhibit heptocellular (liver) cancer. Sorafenib inhibits angiogenesis. My experience as a long-term survivor of an incurable cancer called multiple myeloma, is that conventional, FDA approved chemotherapy is expensive and caused short and long-term side effects. Research indicates that evidence-based integrative therapies can enhance the efficacy of conventional chemo while reducing the toxicity and side effects.
Sorafenib is a targeted therapy used in the treatment of advanced renal cell carcinoma (RCC), which is the most common type of kidney cancer in adults. Like any medical intervention, Sorafenib has both risks and potential benefits. It’s important to note that the decision to use Sorafenib or any other chemotherapy agent should be made in consultation with a healthcare professional who can assess the individual patient’s condition and medical history. Here are some general risks and benefits associated with Sorafenib for kidney cancer:
Benefits:
Risks:
Integrating chemotherapy (Sorafenib) with evidence-based non-conventional therapies such as curcumin, resveratrol and quercetin is not an FDA approved standard-of-care therapy approach. Don’t be surprised if your oncologist disagrees with this therapy plan.
In my experience, cancer patients and survivors must utilize the best of both conventional and evidence-based non-conventional therapies in order to live their best, longest life.
Have you been diagnosed with liver cancer? What stage? Let me know if you have any questions-
David.PeopleBeatingCancer@gmail.com.
Thank you,
David Emerson
“Hepatocellular carcinoma (HCC) is among the most common cancer diseases worldwide.
In 2007, sorafenib, a multi-tyrosine kinase and angiogenesis inhibitor, was approved as the first systemic treatment for advanced stage HCC.
Other active targeted compounds, either inhibitors of angiogenesis and/or growth factors, are currently being investigated in numerous clinical trials.
Over the last 12 mo, several retrospective or prospective cohort studies combining TACE and sorafenib have been published. Nevertheless, robust results of the efficacy and tolerability of such combination strategies as proven by randomized, controlled trials are awaited in the next two years…”
“Patients with unresectable HCC, for whom the decision to treat with sorafenib, based on the approved label and prescribing guidelines, had been taken by their physician…
Hepatocellular carcinoma (HCC) is now the third leading cause of cancer-related death and the fifth most common malignancy in men; the seventh in women 1,2.
The major risk factors for HCC include
The vast majority (70–90%) of HCC cases occur in the context of liver cirrhosis 5, and consequently many patients present with hepatic dysfunction and experience a high rate of comorbidity. HCC is therefore a heterogeneous disease in terms of aetiology as well as clinical presentation and behaviour, thus presenting challenges for disease management 6…
Sorafenib is a multikinase inhibitor used for the treatment of uHCC 10. Two Phase III studies (SHARP and Asia-Pacific) demonstrated significant improvements in overall survival in uHCC patients, the majority of whom had Child-Pugh A 11,12, and sorafenib is suggested as first-line therapy in HCC patients with advanced-stage disease 13…
Patient demographics and disease characteristics were generally similar between patients receiving an initial sorafenib dose of 400 or 800 mg.
“An angiogenesis inhibitor is a substance that inhibits the growth of new blood vessels (angiogenesis). Some angiogenesis inhibitors are endogenous and a normal part of the body’s control and others are obtained exogenously through pharmaceutical drugs or diet…”